



doseology

Doseology Announces Proposed Share Consolidation

Kelowna, British Columbia, February 8, 2024 – **Doseology Sciences Inc.** (CSE: **MOOD**) (OTCQB: **DOSEF**) (FSE: **VU7**) (“Doseology” or the “Company”), Doseology, an innovator in functional mushroom wellness products, announces its intention to consolidate its outstanding common shares on the basis of ten (10) existing common shares for one (1) new common share of the Company (the “**Consolidation**”). The Consolidation is the first step by the Company to stabilize its financial position and reflects management’s confidence in the Company’s future prospects. The Company believes that, overall, a share consolidation can be a strategic move for a public company to improve its financial position, increase shareholder value, and enhance its market perception.

The Company's present issued and outstanding capital of 44,005,250 common shares will be reduced to approximately 4,400,525 common shares after the proposed Consolidation. No fractional shares will be issued pursuant to the Consolidation. Any fractional shares will be rounded to the nearest whole number of common shares.

Once the Company has received the required approvals, registered shareholders of the Company will receive a transmittal letter from the Company's registrar and transfer agent with instructions on how to exchange their pre-consolidated shares for post-consolidated shares.

The Company will be obtaining new CUSIP and ISIN numbers for the Consolidation. The effective date of the Consolidation, and the new CUSIP and ISIN numbers, will be disclosed in a subsequent news release.

Notwithstanding the foregoing, the board of directors may, at its discretion, determine to amend the terms or to not to move forward with the Consolidation.

About Doseology Sciences Inc. (CSE: **MOOD) (OTCQB: **DOSEF**) (FSE: **VU7**)**

Doseology specializes in premium functional mushroom and adaptogenic herbal supplements that are stacked for targeted results. Our products are science-backed and health expert-formulated, addressing today's top wellness needs. With 100% mushroom fruiting bodies for maximum purity and potency, we leave no room for compromise. Our liquid format ensures faster absorption for an efficient wellness experience. At Doseology, we're committed to optimizing well-being through the power of nature, offering investors an opportunity to join our journey toward optimal wellness.

On behalf of the Board of Directors,
Shawn Balaghi
Interim Chief Executive Officer
Doseology Sciences Inc.

For further information contact:

Investor Relations: investor@doseology.com

Sales Inquiries: hello@doseology.com

Telephone: 236-349-0064

Website: doseology.com

Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.

The CSE does not accept responsibility for the adequacy or accuracy of this release.